NYSE$DVA
DaVita HealthCare Partners Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
DaVita's financial performance was strong in Q2 2021, with significant growth in earnings per share and advancements in integrated kidney care capabilities.
DaVita Inc. reported a strong quarter with diluted earnings per share from continuing operations increasing by 63.0% year-over-year. The company saw progress in combating COVID-19 and accelerated investments in integrated kidney care capabilities, growing the number of patients under value-based care arrangements to approximately 10% of the U.S. dialysis patient census.
- Consolidated revenues reached $2.917 billion.
- Operating income amounted to $490 million.
- Diluted earnings per share was $2.64.
- Operating cash flow and free cash flow from continuing operations were $680 million and $503 million, respectively.
Headline financials
Revenue & EPS history
DaVita · Revenue · Quarterly
$2.92B
Revenue by segment
DaVita · $2.85B total across 2 segments · Q2 2021
- U.S. Dialysis Patient Services$2.68B+0.0%93.9%
- International Dialysis Patient Service$174M+34.9%6.1%
Forward guidance
DaVita provided its 2021 financial outlook, with adjusted operating income expected to be between $1.8 billion and $1.875 billion, adjusted diluted net income from continuing operations per share attributable to DaVita Inc. between $8.80 and $9.40, and free cash flow from continuing operations between $1 billion and $1.2 billion.
Tailwinds
- Adjusted operating income is projected to be between $1,800 million and $1,875 million.
- Adjusted diluted net income from continuing operations per share is expected to range from $8.80 to $9.40.
- Free cash flow from continuing operations is anticipated to be between $1,000 million and $1,200 million.
- The company is focused on growing its integrated kidney care business.
- DaVita is actively managing its capital structure through stock repurchases.
Headwinds
- The widespread impact of the COVID-19 pandemic continues to generate significant risk and uncertainty.
- Future results could vary materially from the guidance provided due to the pandemic.
- Guidance excludes certain items, including foreign currency fluctuations, which may be significant.
- There is continued downward pressure on average realized payment rates from commercial payor plans.
- Healthcare reform and changes in legislation or regulations could reduce coverage or reimbursement rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.6%
Avg return
30 days after
54%
39 / 72 earnings
Positive
+14.7%
Q3 2019
Best reaction
-24.5%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +22.2% | +22.4% | |
| Q4 2025 | +11.0% | +26.7% | +34.9% | |
| Q3 2025 | -6.0% | -5.2% | -5.4% | |
| Q1 2025 | -0.2% | +0.7% | -4.9% | |
| Q4 2024 | -11.1% | -12.5% | -19.0% | |
| Q3 2024 | -10.1% | -9.8% | +5.5% | |
| Q2 2024 | -1.1% | +3.6% | +9.8% | |
| Q1 2024 | -3.8% | -1.5% | +5.3% | |
| Q4 2023 | +8.0% | +6.9% | +19.0% | |
| Q3 2023 | +7.4% | +5.1% | +33.9% | |
| Q2 2023 | +6.7% | +8.6% | +1.0% | |
| Q1 2023 | +13.8% | +5.9% | +13.7% | |
| Q4 2022 | -0.3% | -0.3% | -8.4% | |
| Q3 2022 | -24.5% | -27.9% | -23.6% | |
| Q2 2022 | +2.7% | +1.8% | +1.3% | |
| Q1 2022 | -7.1% | -5.0% | -12.7% | |
| Q4 2021 | -1.2% | +3.5% | -2.6% | |
| Q3 2021 | -6.9% | -6.2% | -12.3% | |
| Q2 2021 | +10.2% | +9.7% | +10.0% | |
| Q1 2021 | +2.8% | +8.9% | +6.0% | |
| Q4 2020 | -7.4% | -8.1% | -4.4% | |
| Q3 2020 | -0.0% | +7.7% | +27.4% | |
| Q2 2020 | -4.3% | -8.5% | -4.8% | |
| Q1 2020 | +9.6% | +7.5% | +9.7% | |
| Q4 2019 | +8.8% | +5.7% | -8.0% | |
| Q3 2019 | +14.7% | +13.6% | +17.9% | |
| Q2 2019 | +0.4% | -1.5% | -5.8% | |
| Q1 2019 | -10.4% | -9.8% | -19.4% | |
| Q4 2018 | +1.3% | +3.0% | -6.7% | |
| Q3 2018 | +1.3% | -1.5% | -14.9% | |
| Q2 2018 | +5.4% | +3.9% | -1.4% | |
| Q1 2018 | +4.7% | +1.2% | +5.9% | |
| Q4 2017 | +1.8% | +0.3% | -5.4% | |
| Q3 2017 | -8.5% | -7.4% | +13.0% | |
| Q2 2017 | -9.8% | -10.9% | -9.6% | |
| Q1 2017 | -3.8% | -5.3% | -2.4% | |
| Q4 2016 | +3.2% | +6.2% | +4.5% | |
| Q3 2016 | +1.1% | +0.1% | +11.1% | |
| Q2 2016 | -6.0% | -10.1% | -16.4% | |
| Q1 2016 | +2.9% | — | — | |
| Q4 2015 | -1.7% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +1.0% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -3.8% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -2.8% | — | — | |
| Q4 2013 | +3.9% | — | — | |
| Q3 2013 | -3.0% | — | — | |
| Q2 2013 | -2.9% | — | — | |
| Q1 2013 | +9.4% | — | — | |
| Q4 2012 | -1.1% | — | — | |
| Q3 2012 | +1.4% | — | — | |
| Q2 2012 | -1.1% | — | — | |
| Q1 2012 | -4.9% | — | — | |
| Q4 2011 | +0.3% | — | — | |
| Q3 2011 | +0.8% | — | — | |
| Q2 2011 | -0.2% | — | — | |
| Q1 2011 | +2.9% | — | — | |
| Q4 2010 | +2.4% | — | — | |
| Q3 2010 | -0.4% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q1 2009 | +1.1% | — | — | |
| Q1 2010 | +0.3% | — | — | |
| Q4 2009 | -0.1% | — | — | |
| Q3 2009 | +0.1% | — | — | |
| Q3 2008 | +0.1% | — | — | |
| Q2 2008 | +4.6% | — | — | |
| Q4 2008 | +4.6% | — | — | |
| Q2 2009 | +4.6% | — | — | |
| Q4 2007 | +4.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro